Found 86 clinical trials
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will …
- 14 views
- 13 Feb, 2022
- 24 locations
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC022F CAR-T cell immunotherapy in relapsed or refractory B-ALL. The study will include 18 subjects to receive GC022F therapy.
- 0 views
- 25 Jan, 2021
- 1 location
Study of IFN- Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia R/R-ALL
The purpose of this study is to evaluate the safety and efficacy of IFN- combined with CAR-T cell therapy in relapsed and refractory acute lymphoblastic leukemia (R/R ALL).
- 0 views
- 25 Jan, 2021
- 1 location
Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL (ALL-001)
-cell acute lymphoblastic leukemia (B-ALL). Two re-induction regimens will be tested (one without pegaspargase and one including pegaspargase) and participants will be followed for disease status
- 0 views
- 18 Jun, 2022
- 4 locations
Phase 1 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
This is a Phase 1, first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic
- 14 views
- 06 Jun, 2022
- 7 locations
CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia
This study aims to evaluate the safety and feasibility of CTA101 in treating patients with relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia.
- 15 views
- 17 Feb, 2022
- 1 location
Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
The purpose of this study is to evaluate the safety and tolerability of CD19-Directed Allogeneic Chimeric Antigen Receptor T- cell (alloCART-19)therapy in pediatric patients with relapsed/refractory acute lymphoblastic leukemiaALL.
- 0 views
- 27 Feb, 2022
- 1 location
CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia
B-cell Lymphoma and B-cell acute lymphoblastic leukemia B-ALL.
- 0 views
- 22 Jan, 2021
- 1 location
Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia
This is an open, single-arm, prospective clinical study to evaluate the safety and efficacy of anti CD19 and CD22 CAR-T cell in the treatment of R/R B-ALL.
- 0 views
- 21 Mar, 2022
- 1 location
A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia
/refractory B-cell acute lymphocytic leukemia
- 0 views
- 19 Jun, 2022
- 2 locations